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a  b  s  t  r  a  c  t
Rotavirus  is one  of the  leading  cause  of  hospitalization  and  outpatients  visits  among  children  under
ﬁve  years.  This  study  evaluated  overall  and  genotype-speciﬁc  vaccine  effectiveness  of oral  monovalent
rotavirus  vaccine  (G1P[8]  strain)  in  preventing  hospital  admission  of Brazilian  children  with  rotavirus
acute  diarrhea.
A hospital  based  case–control  study  was  conducted  in  ﬁve  Regions  of  Brazil  using  the  National  Rotavirus
Acute  Diarrhea  Surveillance  System  from  July  2008  to  August  2011.  A total  of 215  cases  (aged  4–24
months)  admitted  with  conﬁrmed  rotavirus  diarrhea  were  recruited  and  1961  controls  hospitalized
without  diarrhea  were  frequency  matched  by  sex and  age  group  to cases.
Two-dose  adjusted  vaccine  effectiveness  (adjusted  by year  of  birth  and  the  frequency  matching  vari-
ables)  was  76%  (95%CI:  58–86)  lasting  for  two years.  Effectiveness  controlled  by the  available  potential
confounders  was  72% (95%CI:  44–85),  suggesting  no  appreciable  confounding  by  those  factors  for which
adjustment  was  made.  In a half  of  the cases  the  rotavirus  genotype  was  G2P[4] and  in  15% G1P[8].
Genotype-speciﬁc  VE  (two  doses)  was  89%  (95%CI:  78–95), for G1P[8]  and  76%  (95%CI:  64–84)  for  G2P[4].
For  all  G1,  it was  74%  (95%CI:  35–90),  for  all G2, 76% (95%CI:  63–84),  and for all  non  G1/G2  genotypes,
63%  (95%CI:  −27–99).  Effectiveness  for  one  dose  was  62%  (95%CI:  39–97).
Effectiveness of two-dose  monovalent  rotavirus  vaccine  in  preventing  hospital  admission  with
rotavirus  diarrhea  was  high,  lasted  for two  years  and  it was  similar  against  both  G1P[8]  and  G2P[4].  Based
on  the  ﬁndings  of  the  study  we  recommend  the  continued  use  of  rotavirus  in the  Brazilian  National  Immu-
nization  Program  and  the monitoring  of  the early  emergence  of unusual  and  novel  rotavirus  genotypes.
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1. Introduction
Acute diarrhea (AD) is a frequent cause of child hospitalization
and outpatient visits in children under 5 years [1]. In Brazil, before
introduction of the rotavirus vaccine in 2006, about 120.000 hos-
pitalizations a year occurred due to AD in children under ﬁve years
(DATASUS/Ministry of Health of Brazil, 2006).
Rotavirus is the leading cause of severe acute diarrhea in chil-
dren in developed and in developing countries and is the major
cause of death in poor countries [2,3]. Seven groups of rotavirus
have been identiﬁed (A to G) and group A (RV-A) is responsible for
more than 90% of human rotavirus infections [4]. RV-A has great
genetic diversity due almost 60 serotypes (G and P) and the most
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common strains are: G1P[8], G2P[4], G3P[8], G4P[8] and G9P[8] [5].
In Brazil, between 12% and 42% of children under 5 years with diar-
rhea had positive stool samples for RV-A before the introduction
of the RV-A vaccine. This increased from 22% to 38% in children
hospitalized for AD [6,7]. More than 51 genotype combinations
were reported and the most common genotypes described were
G1P[8], G9P[8] and G2P[4] [8].
Vaccination is the better measure to prevent rotavirus [1,2,9]
and its adoption has been recommended by World Health Organi-
zation [10]. An attenuated monovalent human RV-A (G1P[8] strain;
Rotarix®) and a pentavalent bovine-human reassortant (G1,G2,G3,
G4 and P[8] strains; RotaTeq®) are licensed worldwide. Rotarix®
was introduced in the Brazilian National Immunization Program
(BNIP) in 2006 in a two-dose schedule at 2 and 4 months of age and
co-administered with tetravalent, pneumococcal and poliovirus
vaccines.
RV-A vaccine efﬁcacy against severe RV-A AD varied between
more than 90% Europe and Asia, 85% in Latin America, 72% in South
Africa to 49% in Malawi [11–14]. Three case–control studies car-
ried out in a high income country (Belgium) [15] and in low to
middle-income countries (El Salvador and Bolivia) [16,17] found a
two-dose vaccine effectiveness of 90%; 76% and 77% respectively
and a one-dose effectiveness of 91%; 51% and 56% respectively
against hospitalization by RV-A AD. In Brazil, two small case con-
trols studies showed a range of 40–85% effectiveness in preventing
hospitalization caused by G2P[4] [18,19]. The reason for varia-
tion in vaccine protection is not clear and has been attributed
to antigen diversity, malnutrition and higher incidence of other
enteric pathogens [20]. There is strong suggestion of cross protec-
tion among genotypes [11–14].
The introduction of RV-A vaccination was followed by a reduc-
tion in child hospitalization due to all causes of AD in Brazil, El
Salvador and Mexico ranging from 17 to 51% [21–23] and a reduc-
tion in mortality from AD in children under 5 years in Brazil of 22%
and in Mexico of 41% [24].
This  study will evaluate the overall effectiveness of the oral
monovalent vaccine, used in routine health services, in preventing
Brazilian child hospitalization with RV-A AD. It will also evaluate
overall and genotype-speciﬁc VE by time since second dose vacci-
nation (up to two years), and genotype-speciﬁc VE.
2.  Methods
2.1. Study design
This  was a hospital based case–control study, frequency-
matched by sex and age group. Hospitals were general hospitals
which received children with a large range of diseases coming from
a similar geographical catchment area. Seventeen of the hospitals
enrolled in the RV-A AD National Surveillance System were invited
to participate in the study, based on having had a large number of
RV-A positive samples in 2007, adequate level of organization of
the unit and data accessibility. After consultation and agreement
on logistical arrangements with the Federal Health Surveillance
(SVS/MS), the epidemiological surveillance of the hospitals and of
the states, the Central Public Health and National Reference Labo-
ratories, 10 hospitals located in ﬁve macro-regions of Brazil (6 state
capital cities and 4 municipalities) were selected.
3. Participants
3.1. Eligible children
Children  were eligible to participate in the study if they were
admitted in the study hospitals, were aged 4 to 24 months
(and therefore old enough to have received their second dose of
rotavirus vaccine) and did not have diarrhea up to three weeks
before admission or during hospitalization. All eligible children
were  listed and screened to exclude children who had any health
condition presumed to reduce vaccine effectiveness (immunodeﬁ-
ciency, gastrointestinal disease (e.g. diverticulitis), malformations
or neoplasm conditions related to vaccine effectiveness, general
signs and symptoms, infectious and parasitic diseases), those who
had received the second dose of vaccine in the 15 days before hospi-
talization, or whose vaccination did not follow the BNIP schedule.
All that fulﬁlled the speciﬁc criteria for either effective’s case or
control were included. This aimed to select controls from the pop-
ulation that produced the cases, as cases hospitalized by AD or by
other diseases were likely to come from the same population given
the universal health care system in Brazil.
3.2. Potential cases and controls
Inclusion criteria for potential cases were: admission with AD
(deﬁned as three or more liquid stools in 24 h, up to 14 days before
admission), stool sample was collected until 48 h after admission
and positive for RV-A and stay in hospital for at least 24 h. Children
were included in the study in the ﬁrst hospitalization only and had
no associate disease.
Inclusion  criteria for controls were: admission from the same
hospitals of the cases with respiratory, genitourinary, muscu-
loskeletal, nervous systems, skin and subcutaneous tissue, ear and
mastoid processes, eye and adnexa diseases, and external causes.
Controls were not included if they had a previous history of RV-
A diarrhea or had a vaccine-preventable disease (as children who
did not receive one vaccine are more likely to not receive other
vaccines).
All potential controls fulﬁlling the criteria above undergone a
further selection for frequency matching, so that the all effective
controls had the same distribution of the main confounding vari-
ables (sex and age group on admission: 4–6 months; 7–11 months
and 12–24 months) as the cases. This approach aimed to select from
the pool of potential controls, an effective control group with the
same distribution of confounders as the effective cases; in the sit-
uation in which more controls than needed were available in the
frequency matched groups they were selected at random. Random
selection of frequency matched effective controls from the pool of
potential controls was  done using the “sample” command of the
Stata version 11.0
3.3.  Effective cases and controls
Cases: All potential cases fulﬁlling the criteria above and had
stools positive for rotavirus conﬁrmed by the reference laboratory
were included.
Controls: All potential controls fulﬁlling the criteria above and
random selected for frequency matching were included.
One  stool sample was  collected up to 48 h after admission as
part of the RV-A AD Surveillance System. Samples were stored
and transported to the LACENs of each State where the hospital
was located, according to the guidelines of the General Coordi-
nation of Public Health Laboratories/Ministry of Health of Brazil
(CGLAB/SVS/MS). RV-A investigation was  done by Enzyme Immune
Assay (EIA), using commercial kits, following the manufacture’ rec-
ommendation (Dako® or Oxoide®).
3.4. Laboratory investigation of potential cases
All positive samples for RV-A and 25% of negative samples were
sent to a reference laboratory. According to the LACEN localiza-
tion, this was either the National Reference Laboratory (Evandro
Chagas Institute [Belém, PA], or a Regional Reference Laboratory
(Adolfo Lutz Institute [São Paulo, SP], and Oswaldo Cruz Institute
[Rio de Janeiro, RJ]). Results were conﬁrmed by EIA and polyac-
rylamide gel electrophoresis (PAGE) according to Leite et al. [25].
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Fecal suspensions and nucleic acids extraction were carried out
according to Leite et al. [25] and Boom et al. [26], respectively.
The RV-Genotyping was conducted using RT-PCR as described by
Das et al. [27] (“G” genotype) and Gentsch et al. [28] (“P” geno-
types). RV-A genotypes were e-mailed to CGLAB/SVS/MS and sent
to the Institute of Collective Health, Federal University of Bahia
(ISC/UFBa).
4. Data collection
Information from cases and controls was collected by interview-
ers who visited all hospitals daily, from July 2008 to August 2011.
Medical records were reviewed and the child’s carer answered a
standard questionnaire on identiﬁcation, clinical history and evo-
lution, socio-economic status, sanitation, feeding and nutritional
status of the child, and maternal reproductive aspects. The vac-
cination status of the child was assessed through the vaccination
card, asked for during hospitalization. Also, data were obtained by
home visits, telephone or the family health team of the area of resi-
dence of the child. Vaccination status was classiﬁed according to the
presence and number of doses and time between last dose and hos-
pitalization. Weight at admission was taken from hospital records
and its deﬁcit evaluated according to the weight-age standards of
the National Centre for Health Statistics (NCHS) for boys and girls
[29]. Mother’s skin color was self reported.
Questionnaires for all potential cases and controls were sent to
ISC/UFBa and reviewers conﬁrmed the classiﬁcation of cases and
controls by assessing the inclusion and exclusion criteria.
To  complement data on maternal reproductive period and child
birth we consulted live births routine data (SINASC) from 7 cities.
This system covers 80–90% of births in Brazil. The child age on
admission and on administration of ﬁrst and second doses and
breastfeeding duration were calculated in days at the date of admis-
sion. Cases and controls were classiﬁed into three age-groups,
according to age on admission: 4–6 months, 7–11 months and
12–24 months.
5.  Sample size
The  minimum sample size required (using EPI-INFO 6.0) was 88
cases and 88 controls (for vaccine coverage of 70%, VE of 65%, 95%
conﬁdence interval and 90% power. The achieved sample size of 215
cases and 1961 controls enabled estimation of genotype-speciﬁc
vaccine effectiveness.
6.  Statistical analysis
Vaccine  effectiveness was obtained by multivariable uncondi-
tional logistic regression, which is appropriate when frequency
matching is used. The odds ratio was adjusted for: a) sex and
age both used for frequency-matching, b) year of birth, to control
coverage of vaccine by year and c) robust variance estimation of
Jackknife, with clusters being hospitals. Potential confounders were
included in the ﬁnal logistic model when the p-value of associa-
tion was <0.20 (bivariate analysis). We  used the backward method
to analyze the presence of confounding. The best adjustment was
given by the Akaike information criterion (AIC) [30]. Given the
absence of confounding by measured variables apparent in the
analysis by number of doses, the subsequent analysis by time since
second dose vaccination, genotype- speciﬁc was conducted with-
out controlling for confounders other than age, sex, year of birth,
and robust variance estimation of Jackknife. The frequency of miss-
ing values for any confounding variable was very low (less than
1%), and they were attributed to the category of reference (consid-
ered not exposed) to keep all cases in the analysis. We  repeated the
analysis  stratiﬁed by year of admission to control for increasing vac-
cine coverage with time. A sensitivity analysis (for two doses only)
was done, in which cases and controls with missing vaccination
cards were treated as vaccinated or unvaccinated, so assuming non
differential missingness. The VE was calculated by the following
formula: VE = (1 − odds ratio of vaccination) × 100. Statistical anal-
ysis was  performed with Stata version 12.1 (Copyright 1985–2011
StataCorp).
Ethics: This study was  approved by the Committee of ISC/UFBa
(Protocol 017-08/CEP/ISC-2008). Carers of participating children
signed a written informed consent form.
7. Results
7.1. Study population
A  total of 4955 eligible children aged between 4 and 24 months
were recruited into the study from July 2008 to August 2011. Of
these, 697 children did not fulﬁll the criteria of inclusion related to
information on vaccination: 268 did not have a vaccine card; 299
had received vaccination in a different schedule from that recom-
mended by the BNIP; and 130 had received the second dose fewer
than 15 days before admission. (Fig. 1 shows the breakdown of
exclusions for effective cases and controls). In addition, 298 eligi-
ble children with AD did not fulﬁll the criteria of inclusion related to
the stool sample collection: in 202 a stool sample was not collected;
in 33 the samples were lost, and in 63 the sample was  collected too
long after admission. Samples of 965 potential cases were tested
for RV-A with the following results: 722 were negative (of which
142 had another virus identiﬁed and 28 were positive on the ﬁrst
test but negative in the reference laboratory) and 215 were positive
for RV-A conﬁrmed by EIA and/or PAGE and RT-PCR. Of  all eligible
children for controls, 191 had developed diarrhea during hospital-
ization and were not selected to the study and 843 were not needed
given the frequency match. A total of 215 effective cases and 1961
effective controls were recruited.
Characteristics of the study population are presented in the
Supplementary tables (1a,1b,1c). The mean age of the cases and
controls was 14 months. Compared to controls, cases had lower
socio-economic status and sanitary level, their mothers had fewer
years of schooling and their families lived in smaller houses with
many family members and more than one child under 5 years.
Smoking and alcohol consumption during pregnancy and delayed
start of prenatal care were signiﬁcantly higher among cases. Also,
one or more visits to health services or hospitalizations due to diar-
rhea before the current admission were more frequent in cases than
controls. There was a higher proportion of controls who  were never
exclusively breastfed (12.1%) compared with cases (7.4%).
The  use of vaccine between cases and controls was signiﬁcantly
different: 31.2% (67) cases were not vaccinated compared with
10.3% (201) of controls, whereas 53.5% (115) of the cases and 75.5%
(1481) of the controls had received two doses of vaccine.
Of  the children up to two years admitted to hospital with AD,
22.3% were RV-A positive and 156 (73%) were genotyped. The dis-
tribution of RV-A G and P genotypes is presented in Fig. 2 and
Supplementary Table 2 G and P genotypes were identiﬁed in 135
(63.3%) of all RV-A positive samples (n = 215), and only “G” or “P”
types in 21 samples. There was a predominance of the G2P [4]
genotype (51.3%, n = 80) followed by G1P [8] (15.4%, n = 24). Of all
observed genotypes, G2 was found in 57% (n = 89) and G1 in 23%
(n = 36). The other genotypes characterized were: mixed groups
(n = 14), G9 (n = 6), G3 (n = 3), and unusual strains such as G12 (n = 2)
and Group C (n = 1). Mixed infections and unusual genotypes were
identiﬁed in 10.9% of the RV-A positive samples.
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Fig. 1. Study population.
Fig. 2. Genotypes circulating in Brazil from 2008 to 2011.
8. Vaccine effectiveness
The  two-dose adjusted VE (adjusted for year of birth and the
frequency matching variables) was 76% (95%CI: 58–86) (Table 1).
Effectiveness controlled by the available potential confounders
was very similar (72%, 95%CI: 44–85), suggesting no apprecia-
ble confounding by those factors for which adjustment was
made.
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Table  1
Effectiveness of oral monovalent rotavirus vaccine in preventing hospital admission in Brazilian children with rotavirus acute diarrhea by number of doses received.
Vaccination by Case Control ORa VEa ORadjb VEb
Number of doses n n (95%CI) (95%CI) (95%CI) (95%CI)
Unvaccinated 67 201 1 – 1 –
Fully  vaccinated (two doses) 115 1481 0.24 (0.14–0.42) 76 (58–86) 0.28 (0.15–0.56) 72 (44–85)
Partially  vaccinated (one dose) 33 279 0.38 (0.23–0.61) 62 (39–77) 0.40 (0.25–0.63) 60 (37–75)
AICc 1318.253 1194.454
a Odds ratio adjusted by year of birth and variables (sex and age group) used for frequency matching, and robust variance estimation of Jaccknife, where the clusters were
the  hospitals. The vaccine effectiveness (VE) was  calculated by (1 − OR) × 100%.
b Odds ratio adjusted by year of birth and variables (sex and age group) of frequency matching and confounders (mother’s schooling, mother’s absence from home, smoking
during pregnancy, type and regularity of water supply, number of AD hospitalizations before current admission and exclusive breastfeeding) and robust variance estimation
of  Jaccknife, where the clusters were the hospitals.cAkaike information criteria for measuring the goodness of ﬁt of the statistic model.
We  excluded a similar proportion of cases (5.7%) and controls
(5.3%) because they did not have cards. Sensitivity analysis showed
that if they were included as vaccinated, VE (two doses) would be
66% (95%CI: 42–80) and if included as unvaccinated VE would be
74% (95%CI: 53–86).
The  VE (adjusted for year of birth and the frequency matching
variables) for one dose was 62% (95%CI: 39–97) and one dose VE
adjusted for other potential confounders was 60% (95%CI: 37–75).
Table 2 shows that VE was similar in those with time since sec-
ond dose vaccination until hospitalization stratiﬁed by one year
(71%; 95%CI: 54–82) and two years (78%; 95%CI: 52–90). The VE
for G1P[8] and G2P[4] by time since second dose vaccination was
marginally higher for G1P[8](90%; 95%CI:-0.92–-100 for one year
and 89%; 95%CI: 0.01–-99 for two years) than G2P[4] (77%; 95%CI:
57–88 for one year and 75%; 95%CI: 56–86 for two years) signiﬁcant.
Table 3 presents genotype-speciﬁc VE by number of doses. VE
(two doses) was 89% (95%CI: 78–95) for G1P[8]; 76% (95%CI: 64–84)
for G2P [4]; 74% (95%CI: 35–90) for all G1; 76% (95%CI: 63–84) for
all G2 and 63% (95%IC: −27–99) for all the non G1/G2 genotypes.
Estimated VE remained very similar when analysis was strati-
ﬁed by year of admission suggesting that VE did not change with
increasing vaccine coverage (data not presented).
9. Discussion
Two-dose VE was 76% (95%CI: 44–85), in spite of the great diver-
sity of rotavirus genotypes circulating in Brazil and a predominance
of G2P[4] genotype (51.3%). We  found a 10.9% mixed and unusual
genotypes as expected in developing countries [31,32]. The VE
lasted  for two years after second dose vaccination and it was higher
for G1P[8] than G2P[4].
Variation  of RV-A vaccine efﬁcacy and effectiveness have been
reported in the literature: efﬁcacy was higher in Europe (96.4%
against RV-A severe AD) [11] than in a low income country (Malawi,
49.2% against all diarrhea and 57.5% against hospitalized diarrhea)
[13] and in countries with high mortality (63%) [33]. In the middle
income countries of Latin America [12], efﬁcacy was 84.8% against
severe AD; in South Africa it was 72.2% against all diarrhea [13]. This
study showed similar effectiveness to that found in El Salvador [16]
and Bolivia [17] (73% and 76% for severe diarrhea) and in a smaller
study in Brazil [18] (75.8% against hospitalized diarrhea), but lower
than in Belgium (90%) [15].
Two-dose VE remained high for two years. This is similar to other
countries with low mortality; but different from some countries
with high mortality where VE decreases in the second year after
vaccination [5]. A recent study in Nicaragua also found no wan-
ing for the pentavalent vaccine in children aged 12 months or
more with very severe AD [34]. Other reasons for the ﬁnding that
effectiveness did not decrease in the second year in our study are:
we explored VE from time since second dose vaccine while most
countries estimated VE by time since birth; and we estimated VE
against severe cases only. Besides, declines observed in other stud-
ies could be related to the small numbers to estimate effectiveness
in the second year of life [35]. There is no agreement as to the rea-
sons for the variation in VE and in duration of VE in the literature.
The fact that effectiveness in Brazil was similar to other middle
income countries in terms of overall protection against hospital-
ized AD and similar to European countries in relation to waning
might help to advance in this exploration.
Table 2
Effectiveness of oral monovalent rotavirus vaccine in preventing hospital admission in Brazilian children with rotavirus acute diarrhea (overall and genotype-speciﬁc)
stratiﬁed by time from receiving the second dose of vaccine until hospital admission.
Time since the Case Control ORa VEa
Second dose n n (95%CI) (95%CI)
Overall
Unvaccinated 67 201 1 –
<1  year 71 938 0.26 (0.16–0.42) 74 (58–84)
1  to 2 years 44 543 0.22 (0.10–0.46) 78 (54–90)
AIC b(1114.384)
G1P[8]
Unvaccinated  9 201 1 –
<1  year 4 938 0.10 (0.005–1.92) 90 (-0.92–100)
1  to 2 years 3 543 0.11 (0.01–99) 89 (0.01–99)
AIC b (168.4906)
G2P[4]
Unvaccinated  25 201 1 –
<1  year 22 938 0.23 (0.12–0.43) 77 (57–88)
1  to 2 years 19 543 0.25 (0.14–0.44) 75 (56–86)
AIC b (533.5553)
a Odds Ratio adjusted by year of birth and variables (sex and age group) used for frequency matching, and robust variance estimation of Jaccknife, where the clusters were
the  hospitals. The vaccine effectiveness (VE) was  calculated by (1 − OR) × 100%.
b Akaike information criteria for measuring the goodness of ﬁt of the statistic model.
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Table  3
Genotype-speciﬁc vaccine effectiveness of oral monovalent rotavirus vaccine by number of doses received.
Vaccination by Case Control ORa VEa
Rotavirus genotype n n (95%CI) (95%CI)
G1P[8]
Unvaccinated 9 201 1 –
Fully  vaccinated (two doses) 7 1481 0.11 (0.05–0.22) 89 (78–95)
Partially  vaccinated (one dose) 8 279 0.69 (0.30–1.57) 31 (−57–70)
AIC b(236.815)
G2P[4]
Unvaccinated 25 201 1 –
Fully  vaccinated (two doses) 41 1481 0.24 (0.16–0.36) 76 (64–84)
Partially  vaccinated (one dose) 14 279 0.43 (0.22–0.85) 57 (15–78)
AIC b (641.170)
G1
Unvaccinated 10 201 1 –
Fully  vaccinated (two doses) 18 1481 0.26 (0.10–0.65) 74  (35–90)
Partially  vaccinated (one dose) 8 279 0.62 (0.22–1.79) 38 (−79–78)
AIC b (350.510)
G2
Unvaccinated 29 201 1 –
Fully  vaccinated (two doses) 50 1481 0.24 (0.16–0.37) 76 (63–84)
Partially  vaccinated (one dose) 17 279 0.44 (0.26–0.74) 56 (26–74)
AIC b (743.862)
Non G1/G2
Unvaccinated 3 201 1 –
Fully  vaccinated (two doses) 6 1481 0.37 (0.11–1.27) 63 (−27–99)
Partially  vaccinated (one dose) 2 279 0.47 (0.72–3.09) 53 (−2.09–28)
AIC b (137.232)
a Odds ratio adjusted by year of birth and variables (sex and age group) used for frequency matching, and robust variance estimation of Jaccknife, where the clusters were
the  hospitals. The vaccine effectiveness (VE) was calculated by (1 − OR) × 100%.
b Akaike information criteria for measuring the goodness of ﬁt of the statistic model.
A single dose offered some protection, consistent with the lit-
erature (although the VE was higher than in El Salvador [16] and
Bolivia [17] and lower than in Belgium (91%)) [15].
The  good effectiveness identiﬁed is consistent with the reduc-
tion in the rate of child hospitalization and mortality by AD in Brazil
following the introduction of vaccine in Brazil [21].
Genotype-speciﬁc VE was high for G1P[8] (89%) and slightly
lower for G2P[4] (76%) indicating a degree of cross protec-
tion. Animal models shown that immunity to group A rotavirus
(RVA) present homotypic and heterotypic components. Repeat
RVA infections acquired naturally or by vaccination, increase pro-
tective immunity to include multiple serotypes, as indicated by
development of cross-neutralizing antibodies and cross-reactive
epitope-blocking antibodies speciﬁc for VP7 and VP4 antigens. In
the human vaccine clinical trials (monovalent, Rotarix®; penta-
valent, RotaTeq®) as well as in the follow-up studies, both vaccines
presented homotypic as well as heterotypic protection against
different RVA genotypes, including G2P[4] and G9P[8] genotypes
[12,19,36,37].
Genotype speciﬁc VE also remained high in the second year, in
contrast with the ﬁndings for middle income countries. VE was 74%
for all G1 types, 76% for all G2 types and lower for the non G1/G2
type (63%), although numbers were small. The result of VE against
G2P[4] is similar to the two small studies carried out in Brazil (75.4%
to 77% to G2P[4]) but unlike them, effectiveness against both G1P[8]
and G2P[4] did not fall in the second year [18,19].
There is a discussion as to whether vaccine use leads to serotype
replacement [19]. The high effectiveness against both G1P[8] and
G2P[4] suggests that the predominance of G2P[4] is most likely a
cyclical pattern of rotavirus strains occurrence in Brazil as previ-
ously reported [38,39].
This  study avoided the possibility of artiﬁcially reducing effec-
tiveness by using controls without diarrhea rather than controls
with diarrhea and (potential false) no rotavirus in stool. Using EIA,
PAGE and RT-PCR we conﬁrmed that all cases were true cases of
RV-A.
The data collection strategy allowed us to obtain individual data,
to control for possible confounding and verify interactions in over-
all VE. After controlling for seven variables, no confounding was
identiﬁed.
We were unable to investigate either if effectiveness declines
after two years of second dose vaccine or whether there is an inter-
action with oral poliovirus vaccine as the two vaccines are given
at the same time. We  assumed non differential missingness in the
sensitivity analysis. Although this was a case control study recall
bias is not relevant because we did not rely on recall of vaccina-
tion; we used a record (vaccine card) for establishment of the main
exposure.
Only 73% of genotypes of the RV-A positive sample were iden-
tiﬁed. This could hide the circulation of other genotypes, although,
we were able to estimate genotype-speciﬁc VE for the most com-
mon circulating strains.
In  conclusion, we  showed consistent effectiveness of two-dose
oral monovalent vaccine in preventing hospital admissions of
Brazilian children with RV-A AD, closer to European than Africa VE.
Protection lasted for two  years and it was  similar against G1P[8] and
G2P[4] and slightly lower against non G1/G2.The ﬁrst dose already
conferred some protection.
The  ﬁndings of the study supports the continued use of rotavirus
in the Brazilian National Immunization Program and the monitor-
ing for early detection of emergence of unusual and novel rotavirus
genotypes.
Since this vaccine (which requires only two doses and is co-
administered with other vaccines) provides adequate protection,
the beneﬁts of a change to a multivalent vaccine requiring three
doses might are questionable: this may  not increase protection and
lead to incomplete vaccination schemes.
It might be useful to conduct cost-effectiveness stud-
ies to inform national immunization policy. In addition,
other effectiveness studies should investigate what is behind
the observed variation in monovalent rotavirus vaccine
VE.
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Finally, it is important to identify early emergence of unusual
and novel rotavirus genotypes so that the vaccine effectiveness can
be veriﬁed.
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